As of 2025-05-24, the Intrinsic Value of Adaptimmune Therapeutics PLC (ADAP) is (127.92) USD. This ADAP valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.28 USD, the upside of Adaptimmune Therapeutics PLC is -45,770.60%.
The range of the Intrinsic Value is (248.72) - (86.82) USD
Based on its market price of 0.28 USD and our intrinsic valuation, Adaptimmune Therapeutics PLC (ADAP) is overvalued by 45,770.60%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (248.72) - (86.82) | (127.92) | -45770.6% |
| DCF (Growth 10y) | (522.72) - (1,571.56) | (789.08) | -281815.4% |
| DCF (EBITDA 5y) | (22.10) - (25.98) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (131.79) - (156.09) | (1,234.50) | -123450.0% |
| Fair Value | -2.73 - -2.73 | -2.73 | -1,074.72% |
| P/E | (0.01) - (0.02) | (0.01) | -105.1% |
| EV/EBITDA | (4.10) - (2.17) | (3.58) | -1379.6% |
| EPV | (5.26) - (6.66) | (5.96) | -2227.4% |
| DDM - Stable | (2.77) - (12.82) | (7.79) | -2882.9% |
| DDM - Multi | (25.31) - (94.05) | (40.24) | -14466.6% |
| Market Cap (mil) | 68.79 |
| Beta | 0.20 |
| Outstanding shares (mil) | 245.60 |
| Enterprise Value (mil) | 53.15 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.60% |
| Cost of Debt | 7.00% |
| WACC | 7.89% |